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tissue-specific gene expression using the upstream activating sequence (UaS)-GAL4 binary system has facilitated genetic dissection of many biological processes in Drosophila melanogaster. Refining GAL4 expression patterns or independently manipulating multiple cell populations using additional binary systems are common experimental goals. to simplify these processes, we developed a convertible genetic platform, the integrase swappable in vivo targeting element (InSItE) system. this approach allows GAL4 to be replaced with any other sequence, placing different genetic effectors under the control of the same regulatory elements. Using InSItE, GAL4 can be replaced with LexA or QF, allowing an expression pattern to be repurposed. GAL4 can also be replaced with GAL80 or split-GAL4 hemi-drivers, allowing intersectional approaches to refine expression patterns. the exchanges occur through efficient in vivo manipulations, making it possible to generate many swaps in parallel. this system is modular, allowing future genetic tools to be easily incorporated into the existing framework.
Many in vivo manipulations rely on directing gene expression to a specific tissue or to a particular developmental time. There are two basic methods to do this. In one approach, transposable elements carrying genetic effectors with minimal promoters are inserted into the genome, and expression is driven by local gene regulatory elements 1, 2 . Alternatively, regulatory elements can be fused to genetic effectors in vitro and reinserted in the genome [3] [4] [5] . Such enhancer traps and enhancer fusions have been powerful tools in cell biology, development, physiology and neuroscience [6] [7] [8] [9] .
In Drosophila melanogaster, the upstream activating sequence (UAS)-GAL4 system allows for expression of UAS-linked genes in cells expressing the transcription factor GAL4 (ref. 1). Two additional binary systems, using the LexA and QF transcriptional activators, allow independent manipulation of multiple populations of cells 10, 11 . However, although many enhancer trap and enhancer fusion lines exist, particularly for the UAS-GAL4 system, the expression of such lines is seldom confined to a single tissue or cell type, limiting the resolution of these approaches 4, 12, 13 .
Several strategies exist for using the intersections of partially overlapping expression patterns to generate increased specificity. For example, FLP, GAL4 and QF have been used with FRT-flanked interruption or flip-out cassettes to target subsets of expression patterns 11, [13] [14] [15] . The split-GAL4 system allows GAL4 activity to be reconstituted in cells that express both halves of the hemi-driver 16 . Finally, the GAL80 repressor can be used to subtract the overlap between two expression patterns 12, 17 . Though these intersectional methods are useful for generating lines with more specific gene expression patterns, a drawback of these approaches is that with each elaboration or extension of the GAL4 system, new combinations of these regulatory elements or their reporters frequently need to be designed and, in the worst case, whole libraries need to be regenerated.
Recombinase-mediated cassette exchange (RMCE) methods allow a sequence cassette to be replaced in vivo. Several strategies for RMCE, typically using a microinjected plasmid as the substrate for cassette exchange, have been developed [18] [19] [20] [21] [22] [23] [24] . Several of these approaches rely on Flp recombinase-mediated recombination using wild-type or mutant FRT sites to target an FRT-flanked cassette to a specific locus 20, 21, 23 . Another uses Cre recombinase and a pair of incompatible loxP sites 22 . The Streptomyces phage ΦC31 integrase, which catalyzes irreversible site-specific recombination between two sites (attP and attB) 25, 26 , has had a profound impact on animal transgenesis and has made possible several new RMCE strategies 18, 19 .
We combined these recombination systems into a versatile platform to facilitate the segmentation of complex expression patterns and to allow GAL4 expression patterns to be repurposed. The integrase swappable in vivo targeting element (InSITE) system allows an enhancer trap or enhancer fusion to be rapidly converted from GAL4 to any other sequence (Fig. 1a ). The InSITE system uses an RMCE strategy in which the substrate for RMCE can be genetically derived, allowing replacement of GAL4 simply by crossing flies. We demonstrate that such swaps can be done either entirely genetically, using genomic donor lines, or with a microinjected donor plasmid. As this strategy is highly efficient, it is possible to perform high-throughput swapping of many enhancer trap lines to multiple different effector molecules in parallel. In addition, we describe an enhancer fusion vector that is compatible with this replacement strategy, allowing a single transgene to be diversified in vivo. Finally, because the InSITE system allows GAL4 to be converted into any other sequence, this platform is forwardcompatible with currently unanticipated future technologies.
RESULtS a convertible enhancer-trap platform
The InSITE enhancer trap contains a minimal (P transposase) promoter, the GAL4 transcriptional activator and an attP recognition sequence for ΦC31 integrase 18, 19, 25, 26 (Fig. 1b) . We constructed swappable enhancer traps using two different transposons, the Drosophila melanogaster-specific P element and the piggyBac element, which has been used to transform a wide range of species, from insects to mammals [27] [28] [29] [30] ( Supplementary  Fig. 1 ). PiggyBac elements also have a different insertion spectrum from P elements, facilitating the generation of lines with distinct expression patterns 31 . We established transformants and identified mobile, X chromosome-linked insertions, which allow the isolation of additional lines for enhancer-trap screens, for both transposons. Both the P element and piggyBac transposons (referred to as P{IT. GAL4} and PBac{IT.GAL4}, respectively, in which IT denotes InSITE target) functioned as enhancer traps and were expressed in diverse patterns in the adult brain ( Fig. 1c-e and Supplementary Fig. 2 ).
The InSITE system uses three site-specific recombinases to exchange GAL4 with any other sequence 19 (Fig. 1b) . First, we treated the original enhancer trap with Cre recombinase, which removes the loxP-flanked mini-white marker 32 . Next, we introduced an FRT-flanked genomic donor line together with transgenes expressing Flp recombinase and ΦC31 integrase. In a strategy similar to that used to generate knockout alleles 33 , upon treatment with Flp recombinase, a circular, attB-containing molecule is excised from the donor chromosome ( Fig. 1b) . Targeting of a genomic FRT-flanked cassette to a second FRT-containing locus using Flp recombinase has been previously described 20 . We reasoned that the irreversible nature of ΦC31 integrase-mediated insertion would allow for high-efficiency re-integration of the Flp recombinase-liberated donor molecule into the attP site of the InSITE enhancer trap ( Fig. 1b) . Integration events can be detected by the reappearance of the miniwhite marker. Both constructs contain loxP sites oriented such that when treated with Cre recombinase, the original GAL4 and mini-white marker in the integrated donor are deleted, leaving just the donor sequence. Thus, GAL4 can be replaced with any other sequence, which should then be expressed under the control of the same regulatory elements.
In addition to the purely genetic swap, a microinjected plasmid analogous to the circular molecule that is liberated by Flp recombinase can also be integrated into the attP site of the enhancer trap ( Supplementary Fig. 3) . A similar strategy using a microinjected LexA donor plasmid has recently been described 24 .
an InSItE-compatible enhancer fusion vector Another approach to segmenting complex expression patterns is to use enhancer fusion constructs, in which a DNA fragment corresponding to an endogenous regulatory region is cloned upstream of GAL4 or another effector. This approach has the advantage that lines containing enhancer subfragments are often expressed in fewer cells than enhancer traps, and enhancers can be further subdivided in vitro or the effector molecule can be switched by generating new constructs 4 . To take advantage of the enhancer fusion approach but bypass the need to clone and microinject each new construct, we made an InSITE-compatible enhancer fusion vector ( Fig. 1f) . We cloned an enhancer fragment with a known expression pattern, ortc2 (ref. 34) , into this vector and inserted this construct into the attP2 landing site 25 and one of the Cre recombinase-reduced InSITE enhancer trap lines (PBac{IT.GAL4.w-}0096). Although the presence of tandem attB and attP sites in this vector reduces the rate of transformation, likely through vector suicide via intramolecular recombination, we obtained integrants in both cases using standard injection procedures and verified them by PCR. The insertion into attP2 drove the expected ortc2 expression pattern 34 (data not shown). Such enhancer fusions are fully compatible with the InSITE system.
InSItE genetic donor lines and plasmids
We made a collection of attB-containing genetic donor lines and injectable donor plasmids ( Supplementary Fig. 1 ). All of the reagents described here are publicly available (Online Methods). We established transgenic donor lines, referred to as P{ID.X} (X is the inserted effector gene and ID denotes InSITE donor), for the GAL80 repressor 17 , the GAL4DBD, GAL4AD and VP16AD split-GAL4 hemi-drivers 16 as well as the LexA and QF transcriptional activators 10, 11 (Supplementary Fig. 4 ). Taken together, this collection of donor constructs is a versatile toolkit for manipulating gene expression.
Enhancer trap lines are genetically swappable
To test the efficiency of the conversion procedure, we crossed four enhancer trap lines (PBac{IT.GAL4}1.1, PBac{IT.GAL4}3.1, PBac{IT. GAL4}5.1 and PBac{IT.GAL4}6.1) to Cre recombinase-expressing flies to remove the loxP-flanked mini-white marker 32 . We identified deletions by loss of mini-white expression and confirmed them by PCR ( Fig. 2a,b ). This step of the conversion procedure was highly efficient as we recovered no white + flies after treatment with Cre recombinase. Using an eyeless-FLP transgene (eyFLP2), which expresses Flp recombinase in the eyes, we also confirmed that the donor molecules were readily excised by Flp recombinase, as detected by the loss of mini-white expression 35 (Fig. 2c) .
Next, we crossed eight donor lines, representing all six effectors, to one or more of three different recipient lines, PBac{IT.GAL4. w-}3.1, PBac{IT.GAL4.w-}5.1 and PBac{IT.GAL4.w-}6.1 in flies that also carried a heat shock-inducible Flp recombinase gene and expressed ΦC31 integrase in the germline 19 ( Supplementary  Fig. 5 ). We heat-shocked larvae to liberate the circular donor molecule and crossed the resulting flies to flies carrying eyFLP2 (ref. 35) ( Fig. 2d,e ). The presence of eyFLP2 in the following generation ensured that flies in which the FRT-flanked donor cassette had not been excised were not scored as false positives. For all 13 recipient-donor pairs tested, we recovered many white + putative genetic swap flies (16.7-56.6% of crosses giving at least one white + progeny; Table 1 and Fig. 2f ).
We selected several putative genetic swaps for molecular and functional validation. For 12 of 13 recipient-donor pairs, by PCR analysis we identified successful genetic swaps ( Fig. 2a) , referred to as PBac{IS.X.GAL4} (X is the swapped effector gene, and IS denotes InSITE swap). For one of the recipient-donor pairs, we recovered only aberrant events. In addition to having the PCR products diagnostic for the new junctions created by integration of the genetic donor constructs, the swaps resulted in a loss of PCR products specific to the intact donor transposon ( Fig. 2a) . Sequencing of the junction between the mini-white and GAL4 genes revealed that, as expected, a single FRT site from the genomic donor element was retained between the loxP and attL sites in the integrated constructs ( Fig. 2g) . To complete the swap, we treated these lines with Cre recombinase and confirmed removal of GAL4 and mini-white by PCR ( Fig. 2a) . We refer to the final, reduced constructs as PBac{IS.X.w-}.
In addition to verifying the genetic swap lines, we microinjected a set of attB-containing donor plasmids, along with a ΦC31 integrase helper plasmid, into embryos of one of the three InSITE enhancer trap lines ( Supplementary Fig. 3 ). For all injections we obtained white + integrants, with integration frequencies between 9.5% and 22.0%, and confirmed the integration of all five donor plasmids by PCR. Finally, we treated the integrants with Cre recombinase to remove GAL4 and mini-white, and confirmed the final conversion products by PCR. avoiding genetic swap aberrant events Typically, all integrants into a single attP landing site have similar eye colors 36 (Supplementary Fig. 6 ). But we observed aberrant events with different eye colors for many of the above genetic-swap crosses ( Table 1) . Most of these events retained the original donor transposon, but one FRT site was inactivated ( Supplementary  Fig. 7) . Additionally, we recovered one reciprocal translocation, in which the recipient attP site and the donor attB site were directly fused ( Supplementary Fig. 7 ). Such events have been described previously with ΦC31 integrase-mediated recombination in human cell lines 37 . By selecting appropriate recipient and donor pairs, and following specific markers in the crosses (Online Methods), however, aberrant events can be essentially eliminated.
Functional validation of the enhancer trap swaps
To determine whether the swapped enhancer trap lines were functional, we crossed several Cre recombinase-reduced swaps to appropriate reporters. First, we tested swaps to QF and LexA. In PBac{IT.GAL4.w-}6.1 flies, we observed expression in the antennae and maxillary palps and widely in the adult brain ( Fig. 3a-c) . The PBac{IT.GAL4}1.1 enhancer trap drove expression in a group of neurons in the subesophageal ganglion ( Fig. 3d,e ) as well as several neurons in the central brain. In PBac{IS.QF.w-}6.1, expression of QUAS-mCD8:GFP recapitulated the pattern seen with the UAS-driven expression of PBac{IT.GAL4.w-}6.1 (Fig. 3f-h) . In PBac{IS.LexA.w-}1.1 flies, we detected expression from LexAOp-rCD2:GFP in the subesophageal ganglion but not in the central brain neurons (Fig. 3i,j) . Thus the PBac{IS.LexA.w-}1.1 swap recapitulated some, but not all, features of the original GAL4 expression pattern. Next, we tested the conversion to split-GAL4 hemi-drivers and GAL80. We generated swaps of PBac{IT.GAL4.w-}3.1 to the GAL4DBD, VP16AD and GAL4AD hemi-drivers and GAL80 and assayed expression of these lines in the antennae and antennal lobes (Fig. 4) . In PBac{IT.GAL4.w-}3.1, we observed expression in the antennae of adult flies (Fig. 4a) , in several olfactory glomeruli (Fig. 4f,k) and in several central brain neurons. As expected, both PBac{IS.GAL4DBD.w-}3.1 and elav-VP16AD 16 could not drive UAS-mCD8:GFP expression on their own (Fig. 4b,c,g,h,l,m) . But, PBac{IS.GAL4DBD.w-}3.1/elav-VP16AD drove robust expression in a pattern similar to that in the original GAL4 line (Fig. 4d,i,n and Supplementary Table 1 ). As with PBac{IS.LexA.w-}1.1, we detected a minor difference between the two patterns, with no expression seen in the small number of central brain neurons in the PBac{IS. GAL4DBD.w-}3.1/elav-VP16AD brains (Fig. 4f,i,k,n) .
Neither of the activation domain hemi-driver lines drove UAS-mCD8:GFP expression on its own nor did elav-GAL4DBD 16 (Fig. 4p-r,u-w) . PBac{IS.VP16AD.w-}3.1/elav-GAL4DBD drove expression in a pattern that was similar to but somewhat broader than that in the original PBac{IT.GAL4}3.1, whereas PBac{IS. GAL4AD.w-}3.1/elav-GAL4DBD drove weak expression in a subset of the glomeruli detected in the parent GAL4 line (Fig. 4s,t, x,y and Supplementary Table 1 ). Such differences are consistent with previous reports that the VP16AD hemi-driver is a stronger transcriptional activator than GAL4AD 16, 38 . Similarly, the PBac{IS.VP16AD.w-}3.1-PBac{IS.GAL4DBD.w-}3.1 pair drove expression in an essentially identical set of glomeruli as the parent GAL4 line, whereas PBac{IS. GAL4AD.w-}3.1-PBac{IS.GAL4DBD.w-}3.1 was expressed weakly in an overlapping but restricted subset of glomeruli ( Supplementary  Table 1 ). Likewise, PBac{IS.VP16AD.w-}6.1 in combination with elav-GAL4DBD largely recapitulated the original expression pattern seen for PBac{IT.GAL4}6.1 (Supplementary Fig. 8) .
As expected, PBac{IS.GAL80.w-}3.1 eliminated most expression driven by the original PBac{IT.GAL4}3.1 line (Fig. 4e,j,o) . Similar to the split-GAL4 lines, GAL80 did not target the small group of central brain neurons (Fig. 4f,j,k,o) , suggesting that this expression was influenced by sequences inside GAL4 itself.
For most of the swaps, the resultant expression was strongly predicted by the original GAL4 pattern. In 3 of 10 cases, the expression patterns overlapped with the original pattern but also displayed substantial differences. Expression of PBac{IS.QF.w-}3.1 was similar to that in the original PBac{IT.GAL4.w-}3.1 line in the antennae and olfactory glomeruli, but we observed new expression in a single glial subtype (cortex glia) 39 and in trachea ( Supplementary Fig. 8 and Supplementary Table 1) . In a second case, for PBac{IS.GAL4DBD.w-}6.1, the pattern of expression overlapped with that for PBac{IT.GAL4}6.1 in both the antennae and the adult brain but was much sparser and was not detected in the maxillary palps. Finally, PBac{IS.GAL80.w-}6.1 repression of PBac{IT.GAL4}6.1 was incomplete (Supplementary Fig. 8 ). In this case, as GAL4 and GAL80 are presumably being expressed at similar levels, it is not clear that complete repression would be expected.
dISCUSSIOn
We demonstrated that InSITE enhancer traps can be efficiently swapped and made to express a split-GAL4 hemi-driver, GAL80, LexA or QF. This will allow lines with overlapping expression patterns to be used in an intersectional manner to target restricted subsets of the original patterns. Using this system, it should be possible to generate highly specific driver lines targeting small populations of cells or tissues. This will be useful in many developmental and cell-biological experiments, allowing the tissue-specific requirements of genes to be mapped with high precision and the dissection of neural circuits at the level of single neuron types.
One advantage of the InSITE system is that the effector swap can be done genetically, through a series of crosses, bypassing the labor-intensive step of DNA microinjection. Whereas other approaches exist for repurposing enhancer expression patterns, such as constructed enhancer fusions, these strategies have previously required that new constructs must be cloned and transformed for each new desired fusion 4 . The InSITE-compatible enhancer fusion vector we describe allows one to make a single GAL4 construct and then swap it for any of the available donor lines in vivo. In addition, the InSITE genetic swap approach is easily scalable, making it possible to simultaneously exchange large numbers of lines with multiple donor constructs.
The majority of the swaps captured most features of the original GAL4 expression patterns. In some cases, however, either prominent features of the GAL4 pattern were lost or we observed new expression patterns. These changes may have resulted from differences in the strength or responsiveness of reporter lines. Alternately, the swap may have modified some combination of enhancer spacing and sequence composition flanking the promoter. As the InSITE donors are essentially identical outside the effector sequence, these effects are likely intrinsic properties of the effector sequence itself. Therefore, any approach using these effectors would also likely be subject to such context-specific cryptic regulatory activities. These occasional discrepancies between the original and swapped patterns underscore the importance of having a versatile, high-throughput system that allows many orthogonal intersectional strategies to be quickly tested in parallel.
The modular nature of the InSITE platform makes this system forward-compatible. Recent work has described refinements to the existing binary systems 13, 24, 38 . Such new reagents and many unanticipated future technologies can be readily incorporated into the InSITE system and will be useful in designing additional intersectional strategies.
Although we focused primarily on binary system expression and the refinement of expression patterns, many additional elaborations of this system are possible because of the fact that GAL4 can be replaced with any other sequence. For instance, it is possible to design strategies to mutate or modify loci near the transposon insertion site. In particular, because the genetic swap leaves behind a single FRT site, it is possible to use genetic swap lines together with other FRT-containing transposons (such as the Exelixis and Drosdel collections) to make deletions 31 .
These deletions, which could disrupt nearby genes and regulatory elements, can be designed to leave behind either GAL4 or the swapped effector. This provides another approach to segment complex expression patterns, by altering the surrounding regulatory elements. Thus, the InSITE system is a versatile toolkit both for capturing and manipulating gene activity. As the methods described here use recombinases that work in other model organisms, this system should be easily adaptable. 
OnLInE mEthOdS
Cloning enhancer-trap transposons. For pXL-BacII-attP-Gal4LWL, first, the attP site was excised from pUASTP2 (ref. 18) (obtained from J. Bateman, Bowdoin College) with EcoRI and ligated into the EcoRI site of pBluescript, to make pBS-attP. Next, a linker fragment, SPpolyF/R, was made by annealing and phosphorylating the SPpolyF and PSpolyR oligos (all oligos were obtained from Integrated DNA Technologies; see Supplementary  Table 2 for oligo sequences) and this linker was ligated into PstI and SacI cut pBS-attP, destroying the SacI site, to make pBS-attP∆S3. A second linker fragment, HKpolyF/R, was made with the HKpolyF and KHpolyR oligos. pBS-attP∆S3 was cut with HindIII and KpnI, and the HKpolyF/R linker was inserted to generate pBS-attP∆S + S1.
Next, a fragment containing the P promoter was amplified from pLAPVPRA (D.M.G. and M. Müller, unpublished data) using the pPromF and pPromR primers (see Supplementary  Table 3 for sequences of PCR and sequencing primers). The P promoter fragment was cloned into pCRII-TOPO (Invitrogen), to generate pCRII-Pprom1-2. This vector and pBS-attP∆S + S1 were both digested sequentially with BamHI and HindIII, and the P promoter fragment was cloned into pBS-attP∆S + S1 to make pBS-attP∆S + SPprom1. This vector was cut with BamHI and SacI. A BamHI and SacI fragment containing GAL4 and the hsp70 3′ untranslated region (UTR) was isolated from pGaTB 1 (obtained from M. Wernet, Stanford University) and ligated into pBS-attP∆S + SPprom1 to generate pBS-attPPpromGal4.
In parallel, the mini-white gene was obtained as an EcoRI fragment from pC4YM 40 (from M. Müller, University of Basel) and ligated between two loxP sites into the EcoRI site of pBLL∆ (from M. Müller 40 ) to make pBLL∆-miniwhite1. A NotI, BamHI fragment containing mini-white flanked by loxP sites was isolated and cloned into the NotI, BamHI sites of pXL-BacII-ECFP 30, 41 (obtained from L. Luo, Stanford University) to make pXL-BacIIlox-miniwhite-lox. Finally, to make pXL-BacII-attPGal4LWL, a NotI fragment containing attP-Pprom-GAL4-hsp70 3′ UTR was isolated from pBS-attPPpromGal4 and ligated into the NotI site of pXL-BacII-lox-miniwhite-lox. The correct insert orientation was determined by diagnostic digests and by sequencing with primers pPromF, pPromR, MW300Up and 9-1.
For pXN-attPGal4LWL, a KpnI, BamHI fragment from pXL-BacII-attPGal4LWL was ligated into the KpnI, BamHI sites of pXN 42 (from P. Schedl, Princeton University), between the P element ends. This vector was recut with NotI and BamHI, and a NotI, BamHI fragment containing mini-white flanked by loxP sites was inserted to make pXN-LWL. pXN-LWL was then cut with NotI and was ligated to the NotI fragment containing attP-Pprom-GAL4-hsp70 3′ UTR isolated from pBS-attPPpromGal4 to make pXN-attPGal4LWL. The correct orientation of the insert was confirmed by diagnostic digests and sequencing with the P5′inF and MW5′R primers.
Cloning injectable donor plasmids. For pBPHLWL, two pairs of oligos that encoded a multiple cloning site with the restriction sites KpnI-HindIII-BamHI-NotI-MluI-AscI-XbaI-ClaI-NheI-PacI-SphI-SpeI-BglII-SacI were annealed and phosphorylated to make Oligo1F/R and Oligo2F/R. Next, pBluescriptKSII + was cut with KpnI and XbaI and Oligo1F/R was inserted to generate pBS-Oligo1. pBS-Oligo1 was cut with XbaI and SacI, and Oligo2F/R was ligated into this backbone to make pBSO1O2. Next, a ClaI, SpeI fragment containing the hsp70 3′ UTR was isolated from pGaTB and cloned into the ClaI, SpeI sites of pBSO1O2. The resulting vector was cut with SpeI and BglII, and was ligated to an XbaI, BamHI fragment containing loxP-miniwhite-loxP from pBLL∆-miniwhite1, generating the plasmid pBSO1O2hsp70LWL.
In parallel, the attB site from piB-GFP 18 (obtained from J. Bateman) was isolated as a KpnI, HindIII fragment and cloned into pBluescriptKSII+ to make pBS-attB. A HindIII, BamHI fragment containing the P minimal promoter (from pCRII-Pprom1-2) was ligated into the HindIII, BamHI sites of pBS-attB, to make pBS-attBPprom.
Finally, a KpnI, BamHI fragment containing attB and the minimal P promoter was isolated from pBS-attBPprom and ligated into the KpnI, BamHI sites of pBSO1O2hsp70LWL to generate the pBPHLWL donor plasmid. pBPHLWL was sequenced with primers M13For, M13Rev, hsp3′F, MW5′R, MW3′F, hsp3′R(seq), PpromF(seq), MW5′F(seq), MW2F(seq), MW2R(seq), MW3F(seq), MW3R(seq), MW4F(seq), MW4R(seq), MW6F(seq) and MW6R(seq).
For pBPHLWL-Gal80, a NotI, XbaI fragment containing GAL80 from pCASPTubGAL80 (ref. 17) (obtained from T. Schwabe, Stanford University), was cloned into the NotI, XbaI sites of pBPHLWL. The insert was verified by sequencing using primers PpromF(seq), MW5′R, Gal80F1(seq) and Gal80R1(seq).
For pBPHLWL-Gal4AD, a NotI, AscI fragment containing the GAL4AD-leucine zipper fusion from pActPL-Gal4AD 16 (obtained from Addgene) was inserted in the MCS of pBPHLWL and verified by sequencing with the PpromF(seq) and MW5′R primers.
For pBPHLWL-VP16AD, a NotI, AscI fragment containing the VP16AD-leucine zipper fusion from pActPL-VP16AD 16 (obtained from Addgene) was inserted in the MCS of pBPHLWL and verified by sequencing with the PpromF(seq) and MW5′R primers.
For pBPHLWL-Gal4DBD, a NotI, AscI fragment containing the GAL4DBD-leucine zipper fusion from pActPL-Gal4DBD 16 (obtained from Addgene) was inserted in the MCS of pBPHLWL and verified by sequencing with the PpromF(seq) and MW5′R primers.
For pBPHLWL-LexA, a NotI, XbaI fragment containing LexA from pGD319 (obtained from G. Dietzl, Stanford University) was cloned into the MCS of pBPHLWL and verified by sequencing with primers PpromF(seq), MW5′R, LexA1F and LexA1R.
For pBPHLWL-QF, a BamHI and SpeI fragment containing QF 11 from pXN-FBLWLF-QF was ligated into the BamHI, XbaI sites of pBPHLWL and verified by sequencing with the PpromF(seq) and MW5′R primers.
Cloning genetic donor transposons. For pXN-FBLWLF, two sets of FRT site-containing oligos were used to make 5′FRT(KpnI)F/R and 3′FRT(Not-Sac)F/R. Next, pBS-attBPprom was cut with KpnI and 5′FRT(KpnI)F/R was inserted to generate the plasmid pBSattBPprom + 5′FRT5, which had a tandem insertion of the oligo. The orientation of the insert was verified by sequencing with M13For. To reduce this tandem insert, pBSattBPprom + 5′FRT5 was cut with AscI, gel purified and religated to generate pBSFat-tBPprom. This plasmid was then cut with NotI and SacI, and 3′FRT(Not-Sac)F/R was inserted to make pBSFattBPpromF. Next, a KpnI, XhoI FattBPpromF fragment from pBSFattBPpromF was ligated into the KpnI, SalI sites of the pXN vector to make pXN-FattBPpromF2-1. A linker containing specific restriction sites (NotI-EcoRV-PacI-SphI-AvrII-NheI-MluI-BglII) was made from a pair of oligos (GCNotI F (dXho) and GCNotI R (dXho)) and ligated into the NotI site of pXN-FattBPpromF2-1. This plasmid was cut with BglII and NheI, and an XbaI, BamHI loxP-miniwhite-loxP from pBLL∆-miniwhite1 was inserted to make pXN-FBLWLF. pXN-FBLWLF was confirmed by sequencing with the P5′inF and MW5′R primers.
For pXN-FBLWLF-Gal80, a BamHI, SphI fragment containing GAL80 and the hsp70 3′ UTR from pBPHLWL-Gal80 was cloned into the MCS of pXN-FBLWLF and confirmed by diagnostic digests and sequencing with the P5′inF primer.
For pXN-FBLWLF-GAL4AD, a BamHI, SphI fragment containing GAL4AD and the hsp70 3′ UTR from pBPHLWL-GAL4AD was cloned into the MCS of pXN-FBLWLF and confirmed by diagnostic digests and sequencing with the P5′inF primer.
For pXN-FBLWLF-VP16AD, a BamHI, PacI fragment containing VP16AD and the hsp70 3′ UTR from pBPHLWL-VP16AD was cloned into the MCS of pXN-FBLWLF and confirmed by diagnostic digests and sequencing with the P5′inF primer.
For pXN-FBLWLF-Gal4DBD, a BamHI, PacI fragment containing GAL4DBD and the hsp70 3′ UTR from pBPHLWL-Gal4DBD was cloned into the MCS of pXN-FBLWLF and confirmed by diagnostic digests and sequencing with the P5′inF and MW5′R primers.
For pXN-FBLWLF-LexA, a NotI, PacI fragment containing LexA and the hsp70 3′ UTR from pBPHLWL-LexA was cloned into the MCS of pXN-FBLWLF and confirmed by diagnostic digests and sequencing with the P5′inF primer.
For pXN-FBLWLF-QF, using pBac-GH146-QF-hsp70 (ref. 11) as substrate, QF and hsp70 were separately PCR-amplified with a shared sequence (5′-TAAGCACTAGTGCAGATCTTATCGAT AC-3′) between the QF and hsp70 regions. For QF, the following primers were used: BHI-QF-FOR/QFREV-hsp70-LNKR. For hsp70, the following primers were used: pGaTn-hsp70REV-NotI-BH1/hsp70-FOR-QF-LNKR. The QF and hsp70 PCR products were annealed and the BHI-QF-FOR and pGaTn-hsp70REV-NotI-BH1 primers were used to PCR amplify a BamHI-QF-SpeI-BglII-hsp70-NotI-BamHI cassette, which was cloned into the BamHI site of pXN-FBLWLF. An insert in the correct orientation was verified by sequencing.
Cloning the enhancer fusion vector. For pBMPGal4LWL, pBSO1O2 was cut with BamHI and BglII, and a BamHI fragment containing GAL4, the hsp70 3′ UTR and loxP-flanked miniwhite from pXL-BacII-attPGal4LWL was ligated into these sites to make pBSO1O2-Gal4LWL. A correctly oriented insert was cut with NotI, treated with mung bean nuclease and religated to destroy the NotI site. Next, to make a multi-cloning site, a pair of oligos (PstI-SacI EF linker For and PstI-SacI EF linker Rev) were phosphorylated, annealed and ligated into the SacI and PstI sites of pBS-attP. Next, the multicloning site and attP site were liberated using HindIII and ligated into the HindIII site of pBPHLWL. An insert with the correct orientation was identified and a fragment containing attB, the multi-cloning site, and attP was cut out of this plasmid with KpnI and BamHI. Finally, this fragment was ligated into the KpnI, BamHI sites of pBSO1O2-Gal4LWL to make pBMPGal4LWL.
For pBMPGal4LWL-ortc2b, a fragment containing the ortc2b regulatory region was amplified from pChs-ATTB-OrtC2-Gal4 (ref. 34) (obtained from C.-H. Lee, National Institutes of Health) using the ortc2b For and ortc2b Rev primers. A NotI site was added to the 5′ end of the PCR product, which was then cloned into pCRII-TOPO (Invitrogen). The ortc2b fragment was cut out of pCRII-TOPO with NotI and BamHI and cloned into NotI, BglII cut pBMPGal4LWL.
Fly methods. Flies were grown on molasses food at 22-25 °C. Injections were performed as previously described by Rainbow Transgenic Flies 43 . P element constructs were transformed using a standard ∆2-3 helper plasmid. PiggyBac constructs were transformed using the pBSII-hs-orf 30 helper plasmid (obtained from L. Luo, Stanford University). Injected attB donor constructs (pBPHLWL derivatives) were transformed using the ΦC31 integrase helper plasmid pBS130. Flies were obtained from the Bloomington Drosophila Stock Center (BDSC) (y, w; P{CaryP}attP2) to test the integration of pBMPGal4LWL.
Cre recombinase reductions.
To prepare swappable enhancer trap lines for injection of the donor plasmid (or genetic conversion), females containing a convertible enhancer trap line were crossed to males carrying the Cre recombinase (y, w; MKRS, P{hsFLP}86E/TM6B, P{w[ + mC] = CrewDH2, Tb [1] , or y, w; noc[Sco]/CyO, P{w[ + mC] = CrewDH1, from BDSC). Males containing both the enhancer trap and the Cre recombinase-encoding chromosome were crossed to the appropriate balancer line, and single male progeny were used to establish a balanced white minus enhancer trap stock (Supplementary Fig. 6 ). The clean excision of mini-white was confirmed by PCR. The same procedure was used to remove the mini-white marker and original GAL4 gene from integrant flies. Excision using Cre recombinase was highly efficient, approaching 100%.
Genetic conversion crosses.
To carry out the genetic swap procedure ( Fig. 1b and Supplementary Fig. 5) , first a y, w, hs-FLP, vas-ΦC31 integrase recombinant X chromosome was established. Recombinants were scored for the presence of GFP (marking the J15, vas-ΦC31 integrase transgene 19 ) and then tested by PCR for the presence of FLP recombinase (FLP) (using the FLP Set1 Forward/FLP Set1 Reverse and FLP Set2 Forward/FLP Set2 Reverse primers). y, w, hs-FLP, vas-ΦC31; Recipient(enhancer trap)w-/Balancer stocks were made, and virgins were crossed to genetic donor males (Supplementary Fig. 5) . These flies were allowed to lay eggs for 2-4 days, then flipped onto fresh food. The vials containing the progeny of this cross were then heat-shocked in a 37 °C water bath for 1 h, every day, until most of the progeny had pupated. The resulting progeny had eyes which were either completely white, or had small patches of orange or red variegation ( Fig. 2d,e ). Heat-shocked y, w, hs-FLP, vas-ΦC31; Donor/ + ; Recipient(w-)/ + males were crossed to y, w, eyFLP2; Balancer virgins and white plus putative genetic swaps were balanced. Integration of the genetic donor construct in the enhancer trap was confirmed by PCR. To complete the swap, the enhancer trap containing the integrated genetic donor construct was reduced using Cre recombinase. Genetic donor constructs lose mini-white expression when crossed to eyFLP2, which excises the FRTflanked donor cassette in the eye. At least eight independent lines were tested for the VP16AD, GAL80, GAL4AD, GAL4DBD, LexA, and QF constructs, and every line had white eyes in the presence of eyFLP2 (Fig. 2c) , with the exception of one VP16AD line (P{ID. VP16AD}39.1D1), which was pupal lethal with eyFLP2.
Maintaining the genetic donor lines together with the y, w, hs-FLP, vas-ΦC31 chromosome for many generations may lead to degradation of the donor construct.
Avoiding genetic swap aberrant events. As all aberrant events were associated with the original donor site, crosses should be set up with recipient and donor lines on different chromosomes. This way, putative genetic swap lines that do not map to the recipient chromosome can be immediately discarded. In addition, by using recipient and donor lines with distinct eye colors, the level of mini-white expression can facilitate the identification of bona fide swaps. To avoid reciprocal translocations, recipient and donor lines can be molecularly mapped ( Supplementary  Fig. 4) 44, 45 and selected such that any translocations will be lethal (for instance, by generating a dicentric or acentric chromosome). Finally, by selecting white + flies in the final step that also contain the balancer or dominant marker that was opposite the donor chromosome in the previous generation, it is possible to select against aberrant events. In our experience, selecting matched donors and recipients in this way eliminated all aberrant events. Even if no effort was made to select against aberrant events, the frequency of true events among w + putative swaps was quite high (averaging 51.7%; Table 1 ).
Functional tests of enhancer trap swaps. The following lines were used to functionally test the split-GAL4 enhancer trap swaps: w; P{UAS:2xEGFP}; P{elav-GAL4.DBD}H4A1, w; P{UAS:2xEGFP}; P{elav-GAL4.AD}I1A1, w; P{UAS:2xEGFP}; P{elav-VP16. AD}G3A1 (from BDSC) 16 . For testing the enhancer trap swaps, the UAS:2xEGFP chromosome present in the elav split-GAL4 lines was replaced with UAS:mCD8-GFP 17 . w; LexAop:rCD2-GFP 10 (obtained from C.-H. Lee) reporter lines were used to monitor LexA-driven gene expression. w; P{QUAS-mCD8-GFP.P}5J was used to monitor QF expression 11 . The following injected enhancer trap swap lines were functionally tested: PBac{IS.VP16AD.w-} 6.1(11.1), PBac{IS.GAL80.w-}6.1(39.1), PBac{IS.GAL4AD.w-} 3.1(33.1), PBac{IS.GAL4DBD.w-}3.1(51.1) and PBac{IS.LexA.w-} 1.1 (44.1) . The following genetic swap lines were functionally tested: PBac{IS.VP16AD.w-}6.1(D37-6), PBac{IS.GAL80.w-} 6.1 (E17-30) , PBac{IS.GAL4DBD.w-}6.1 (F32-2) , PBac{IS.GAL80.w-} 3.1 (E17-12) , PBac{IS.VP16AD.w-}3.1 (D33-16) , PBac{IS.QF.w-} 6.1 (Q10B-7) and PBac{IS.QF.w-}3.1(Q12A-10). GFP expression in adult animals was visualized on a Zeiss M2Bio stereomicroscope and fluorescence images were acquired using a SPOT-RT digital camera (Diagnostic Instruments, Inc.).
Confirming Cre-mediated reductions and injected integration events by PCR.
To confirm the deletion of mini-white by Cre, the subsequent integration of the microinjected attB-containing donor construct and the Cre-mediated reduction of the integrant, a set of diagnostic PCR primers was used ( Fig. 2a,b and  Supplementary Fig. 3) . The following primer pairs were used on the piggyBac constructs: MW3′F2/pBAC3′R4, Gal4 3′F2/ MW5′R2, pBAC5′F1/attP R1, Gal4 3′F2/pBAC3′R4, pBSF1/attP R1, pBAC5′F1/attB R1 and construct-specific primer/pBAC3′R4. Construct-specific primers: Gal80 3′F1, Gal4AD 3′F1 (note: also works on VP16AD), Gal4DBD 3′F1, LexA 3′F1, or QF 3′F1.
To confirm integration into the P element constructs (data not shown), the above primer pairs can be used, with two modifications. P5′inF can be used in place of pBAC5′F1, and P3′Rnew2R can be used in place of pBAC3′R4.
Confirming genetic swaps by PCR. The primers that were used to confirm the injection-based enhancer trap swaps were also used to validate the genetic swaps, with one exception. In the genetic swaps, the sequence corresponding to the vector backbone in the injected swaps does not exist, so primer MW3′F2 was substituted for pBSF1 in primer pair number 5. In addition, another set of PCRs using the primer pairs P5′inF/attBR1 (primer pair 8 in Fig. 2b ) and MW3′F2/ P3′Rnew2R (primer pair 9 in Fig. 2b) were done on the genetic swap lines, to confirm the loss of the donor element 5′ and 3′ junctions.
as necessary in Photoshop (Adobe) using cropping and thresholding tools, and assembled into figures using Illustrator (Adobe).
InSITE reagents.
Drosophila stocks, including the mobile, X-linked P element and piggyBac enhancer trap lines (P{IT.GAL4}A134.3 and PBac{IT.GAL4}0315), the y, w, hs-FLP, vas-ΦC31 line, and all of the genetic donor lines shown in Supplementary Figure 4 have been deposited with the Bloomington Drosophila Stock Center. A collection of 100 InSITE enhancer trap lines is available upon request. All plasmids have been deposited with Addgene.
